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Beclin 1 restrains tumorigenesis through Mcl-1
destabilization in an autophagy-independent
reciprocal manner
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Ciro Mercurio1, Clelia Miracco3, Luisa Lanfrancone1, Marco Foiani2,4 & Saverio Minucci1,4,5
Mcl-1 is a unique Bcl-2 family member that plays crucial roles in apoptosis. Apoptosis-
unrelated functions of Mcl-1 are however emerging, further justifying its tight regulation.
Here we unravel a novel mechanism of Mcl-1 regulation mediated by the haplo-insufﬁcient
tumour suppressor Beclin 1. Beclin 1 negatively modulates Mcl-1 stability in a reciprocal
manner whereby depletion of one leads to the stabilization of the other. This co-regulation is
independent of autophagy and of their physical interaction. Both Beclin 1 and Mcl-1 are
deubiquitinated and thus stabilized by binding to a common deubiquitinase, USP9X.
Beclin 1 and Mcl-1 negatively modulate the proteasomal degradation of each other through
competitive displacement of USP9X. The analysis of patient-derived melanoma cells and
tissue samples shows that the levels of Beclin 1 decrease, while Mcl-1 levels subsequently
increase during melanoma progression in a signiﬁcant inter-dependent manner. The
identiﬁed inverse co-regulation of Beclin 1 and Mcl-1 represents a mechanism of functional
counteraction in cancer.
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S
everal types of tumours express abnormally high levels of
Mcl-1 and numerous reports have established a direct link
between elevated levels of Mcl-1 and tumorigenesis, drug
resistance and relapse in those tumours1–7. Mcl-1 plays a key
role in the regulation of apoptosis and its tumour-promoting
properties have been largely attributed to its anti-apoptotic
functions. However, emerging reports now suggest that Mcl-1 is
implicated in other cellular processes that may contribute to its
tumorigenic potential. Recently, Mcl-1 has been implicated
in the regulation of mitochondrial bioenergetics and
morphogenesis8, chemotherapy-induced senescence9, starvation
and Ras oncogene-induced autophagy10,11, suggesting that its
contribution to tumorigenesis may go beyond evading
apoptosis. Targeting Mcl-1 is emerging as a potential
therapeutic strategy12–16 and therefore a deeper understanding
of the mechanisms controlling Mcl-1 levels and function is of
paramount importance. In comparison with other anti-apoptotic
members of the Bcl-2 family, Mcl-1 exhibits some unique features
including its tight regulation by complex mechanisms at the
multiple levels of expression, translation and stability17.
Beclin 1 is a haplo-insufﬁcient tumour suppressor that is
frequently deleted or downregulated in several types of
tumours18–21. Enhanced expression of Beclin 1 is associated
with inhibition of cellular proliferation and diminished in vitro
clonogenic survival11 and xenograft tumour growth19. Owing to
its central role in autophagy, the tumour suppressor function of
Beclin 1 has been initially associated with autophagy. However, it
is not clear whether autophagy solely accounts for Beclin 1
tumour suppression capacity. Increasing evidence suggests that
Beclin 1 may be involved in other processes that contribute to its
tumour-restraining potential22,23.
In the current study, we identify a novel mechanism of
regulation of Mcl-1 mediated by the haplo-insufﬁcient tumour
suppressor Beclin 1 that at the same time acts as a mechanism of
regulation of Beclin 1 itself in an inverse reciprocal manner.
On the basis of our results, we propose that this reciprocal
mechanism contributes to the opposite roles the two proteins play
in the process of tumorigenesis. The ability of Beclin 1 to
modulate Mcl-1 levels represents an autophagy-independent
function of Beclin 1 that could account for an important part
of its tumour-restraining capacity.
Results
Beclin 1 and Mcl-1 are reciprocally co-regulated. Considering
the emerging role of Mcl-1 in mediating starvation-induced
autophagy10,11,24, we ﬁrst assessed the contribution of
endogenous Mcl-1 to the regulation of basal, housekeeping
autophagy. Protein levels of Mcl-1, Bcl-2 or Bcl-xL were depleted
by transiently transfecting 293T cells with two different siRNAs
against each protein or a control siRNA against Luciferase.
Depletion of endogenous Mcl-1 but not of Bcl-2 or Bcl-xL was
sufﬁcient to induce basal autophagy in cells cultured under
nutrient-rich conditions as assessed by conversion of LC3I to II
and decrease in p62 levels (Fig. 1a). Importantly, the induction of
autophagy in response to Mcl-1 depletion was associated with a
marked increase in the levels of Beclin 1 protein, not observed on
depletion of Bcl-2 or Bcl-xL (Fig. 1a). The tight correlation
between decrease in Mcl-1 and increase in Beclin 1 levels was
further conﬁrmed by transfecting 293T cells with a doxycycline-
inducible shRNA construct targeted against Mcl-1. Cells were
then either left untreated or treated with doxycycline for 1, 3 or 5
days. On doxycycline treatment, Mcl-1 levels gradually decreased,
which was concomitant with proportional increase in the levels of
Beclin 1 protein. In the same settings, the levels of other
autophagy regulators, Atg5 and Atg7, remained unchanged,
suggesting a speciﬁc counter regulation between Mcl-1 and Beclin
1 (Fig. 1b). To further explore these ﬁndings, Mcl-1 was
pharmacologically depleted in 293T cells taking advantage of
two kinase inhibitors known to affect Mcl-1 protein levels17.
Treatment of 293T cells with either roscovitine or sorafenib,
which block Mcl-1 transcription and translation, respectively, led
to decrease in Mcl-1 and concomitant increase in Beclin 1 levels.
The BH3 mimetic ABT 737 that does not target Mcl-1 failed to
exert a similar effect, conﬁrming the speciﬁcity of Beclin 1
modulation by Mcl-1 (Fig. 1c).
Thus, RNAi-mediated or pharmacological depletion of Mcl-1
results in Beclin 1 upregulation. To further explore this inverse
correlation between Mcl-1 and Beclin 1 levels, we sought to
examine whether elevation of Mcl-1 levels may conversely lead to
a decline in that of Beclin 1. Mcl-1 protein levels are controlled by
proteasomal degradation as a consequence of ubiquitination by
several E3 ligases including Mule25. It has also been reported that
binding to the BH3-only protein Noxa targets Mcl-1 for
proteasomal degradation26. To study the effect of elevation of
endogenous Mcl-1 level on Beclin 1, 293T cells were transfected
with two different siRNAs raised against either Mule or Noxa to
stabilize Mcl-1. Depletion of Mule or Noxa led to varying
magnitudes of increase in Mcl-1 levels depending on the
efﬁciency of the knockdown, as shown in Fig. 1d. This increase
in Mcl-1 was associated with a tightly corresponding decrease
in Beclin 1 levels in each case. As a control, knocking down the
BH3-only protein Bad, which had no effect on Mcl-1 levels, did
not modulate Beclin 1 levels to any extent (Fig. 1d).
Strikingly, when Beclin 1 protein levels were extinguished using
two different shRNAs, Mcl-1 levels markedly increased indicating
that the modulation between Mcl-1 and Beclin 1 is reciprocal.
The extinction of other autophagy regulators such as Atg5 or
Atg7, which act in the autophagy pathway downstream of Beclin
1, did not have any consequences on Mcl-1 levels (Fig. 1e) further
conﬁrming the speciﬁcity of Beclin 1/Mcl-1 interdependency and
suggesting that this co-regulation is independent of the autophagy
regulatory functions of Beclin 1.
The same Beclin 1/Mcl-1 interdependency was also observed
when we performed similar experiments in HeLa cells, suggesting
that these observations are not limited to 293T cells
(Supplementary Fig. 1). Consistent with the observation that
Beclin 1 can impact the stability of some of its interacting
proteins, we also observed that ablation of Mcl-1 led to increase
in UVRAG and Atg14 levels (Supplementary Fig. 2).
In conclusion, the data presented above indicate that Mcl-1
and Beclin 1 are co-regulated in a negative reciprocal manner
whereby depletion of one leads to the upregulation of the other.
Mcl-1 and Beclin 1 reciprocally modulate their ubiquitination.
To gain insight into the mechanism of reciprocal regulation
between Mcl-1 and Beclin 1, we initially examined the expression
of MCL1 and BECN1 genes in 293T cells depleted of either Beclin
1 or Mcl-1, respectively. No detectable changes in BECN1 gene
expression was observed in cells transfected with two
different siRNAs raised against Mcl-1 compared with control cells
transfected with siRNA against Luciferase as shown by real-time
qPCR (Fig. 2a). Similarly, when Beclin 1 levels were extinguished
by two different shRNAs speciﬁc for the Beclin 1 transcript, no
detectable changes in MCL1 gene expression were observed
(Fig. 2b).
We next investigated whether mRNA translation and protein
biosynthesis play a role in the Beclin 1/Mcl-1 co-regulation. 293T
cells were transfected with siRNAs targeted against Mcl-1 or
Beclin 1 as described above and then treated with or without
the protein translation inhibitor cycloheximide. As shown in
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Fig. 2c,d, inhibition of de novo protein synthesis by cycloheximide
failed to modulate the increase in protein levels to any signiﬁcant
extent as compared with untreated cells, ruling out a role for
protein translation.
Taken together, these data demonstrate that Beclin 1/Mcl-1
negative co-regulation is dependent neither on transcriptional
control nor on modulation of protein synthesis, suggesting that
Mcl-1 and Beclin 1 mutually modulate the protein stability of
each other.
We next sought to examine the contribution of the lysosomal
or proteasomal pathways to the degradation of Mcl-1 and Beclin
1. To this end, we treated 293T cells with speciﬁc pharmacological
inhibitors of the two degradation processes. First, cells were
treated at different time points in the presence or absence of
either Baﬁlomycin A1 or a combination of E64d and pepstatin A,
which are known to inhibit the lysosomal degradation pathway.
As expected, both treatments led to the accumulation of LC3II
conﬁrming the impairment of lysosomal degradation, but no
detectable changes were observed in either Mcl-1 or Beclin 1
protein levels (Fig. 2e).
As opposed to lysosomal inhibition, proteasomal inhibition
upon treatment with either MG132 or Epoxomicin led to an
evident accumulation of Mcl-1 (Fig. 2f), as previously described25.
In sharp contrast to the inverse correlation described earlier,
increase in Mcl-1 protein level on inhibition of the proteasome
was not associated with diminished Beclin 1 levels. Rather, Beclin
1 co-accumulated together with Mcl-1 (Fig. 2f), suggesting that
the ubiquitin-proteasome pathway is the major turnover pathway
for both Mcl-1 and Beclin 1.
On the basis of this observation, we therefore explored the
possibility that Mcl-1 and Beclin 1 can reciprocally modulate the
proteasomal degradation of each other by affecting their
ubiquitination. We assessed Beclin 1 ubiquitination status in
293T cells transfected with two independent siRNAs raised
against Mcl-1. Knockdown of Mcl-1, as compared with control
led to a signiﬁcant reduction in the level of ubiquitinated
Beclin 1. This effect was speciﬁc to Mcl-1 extinction, as siRNAs
raised against other Bcl-2 family members, Bcl-2 or Bcl-xL,
did not have any effect on the level of ubiquitinated Beclin-1
(Fig. 2g).
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Figure 1 | Inverse correlation between Mcl-1 and Beclin 1 levels. (a) Assessment of autophagy markers in 293T cells transfected with the indicated
siRNAs and grown in nutrient-rich medium. (b) Mcl-1 knockdown in 293T cells transfected with tetracycline-inducible shRNA against Mcl-1 and either
treated with Doxycycline (100 ngml 1) or left untreated for the indicated time points. (c) Pharmacological depletion of Mcl-1 in 293T cells treated
with sorafenib (10mM), roscovitine (25mM) or ABT 737 (1mM) as control for the indicated time points. (d) Stabilization of endogenous Mcl-1 and
concurrent decrease in Beclin 1 in 293T cells transfected with the indicated siRNAs. (e) Mcl-1 upregulation upon Beclin 1 knockdown in 293T cells
transfected with the indicated shRNAs.
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Similarly, we also observed signiﬁcant reduction in the level of
ubiquitinated Mcl-1 when Beclin 1 was stably extinguished by
two different shRNAs, as shown in Fig. 2h. Depletion of other
regulators of autophagy Atg5 or Atg7 did not modulate Mcl-1
ubiquitination, further supporting the speciﬁcity of this regulation
and its independency from autophagy.
USP9X deubiquitinase interacts with both Mcl-1 and Beclin 1.
As neither Mcl-1 nor Beclin 1 is known to exhibit direct ubiquitin
ligase or deubiquitinase enzymatic activity, we investigated the
possibility that Mcl-1 and Beclin 1 may indirectly regulate the
ubiquitination of each other through modulating the binding or
the function of other ubiquitination regulators (ubiquitin ligases
or deubiquitinases). To systematically address this possibility, we
proﬁled the entire interactomes of both Mcl-1 and Beclin 1 using
mass spectrometry as an effective strategy for the identiﬁcation of
potential interacting ubiquitination regulators. Lysates from 293T
cells transfected with expression vectors encoding Flag-tagged
Mcl-1 or Beclin 1 were subjected to immunoprecipitation with an
anti-Flag antibody. Interestingly, the mass spectrometric analysis
of the co-immunoprecipitated proteins revealed that the USP9X
deubiquitinase is a common interactor of both Mcl-1 and Beclin 1
(Fig. 3a). These results were then conﬁrmed by immunoblotting
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Figure 2 | Reciprocal regulation between Mcl-1 and Beclin 1 protein stability and ubiquitination. Beclin 1 (a) and Mcl-1 (b) mRNA levels in 293T cells
transfected with the indicated siRNAs/shRNAs. Results are representative of at least three independent experiments. Error bars represent s.e.m.
(c,d) Beclin 1 and Mcl-1 protein levels in 293Tcells transfected with the indicated siRNAs/shRNAs and treated with or without cycloheximide (20 mgml 1)
for 6 h. (e,f) Mcl-1 and Beclin 1 protein levels in 293Tcells treated with the inhibitors of either the lysosomal degradation pathway (100 nM Baﬁlomycin A,
10mg/ml E64dþ Pep) or the proteasome (2.5mM MG132, 25 nM Epoximicin) for the indicated time points. (g,h) Beclin 1 or Mcl-1 were
immunoprecipitated from 293T cells transfected with the indicated siRNAs/shRNAs and assessed for their ubiquitination levels.
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analysis as shown in Fig. 3b, where USP9X is pulled down
speciﬁcally only with Mcl-1 or Beclin 1, but not with Bcl-2 as a
control. As a further control for speciﬁcity, we detected the
presence of Mule, a known Mcl-1 interactor, only in the Mcl-1,
but not the Beclin 1 immunoprecipitate. Furthermore, immu-
noprecipitation of endogenous USP9X showed that the interac-
tion with Mcl-1 and Beclin 1 occurs at the level of endogenous
proteins (Fig. 3c). Finally, immunoﬂuorescence analysis showed
an overlap in Mcl-1, Beclin 1 and USP9X localization
(Supplementary Fig. 3).
USP9X deubiquitinates and stabilizes both Mcl-1 and Beclin 1.
As USP9X has been previously shown to mediate Mcl-1 deubi-
quitination and stabilization7, we examined whether the
interaction between USP9X and Beclin 1 has similar functional
consequences. Endogenous Beclin 1, Mcl-1 or as a control Bcl-2
were immunoprecipitated from 293T cells transfected with
constructs encoding wild type (WT) or enzymatically inactive
mutant (C/S) USP9X. The ubiquitination status of the
immunoprecipitated proteins was assessed by immunoblotting
as described above. Overexpression of wild-type USP9X caused a
signiﬁcant reduction of the ubiquitination of Mcl-1, as expected,
and of Beclin 1, which was not observed on overexpression of the
USP9X catalytic mutant (Fig. 3d). USP9X overexpression,
however, did not affect Bcl-2 to any extent. In line with these
observations, wild-type USP9X overexpression but not the
mutant USP9X C/S led to accumulation of both Mcl-1 and
Beclin 1 as detected by immunoblotting analysis of total cell
lysates (Fig. 3e). This effect seems to be speciﬁc to USP9X, as
overexpression of another deubiquitinase, USP28, led to
stabilization of its known substrate LSD1 but had no effect on
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Figure 3 | USP9X binds, deubiquitinates and stabilizes Beclin 1 and Mcl-1. (a) Full annotation of two USP9X peptides identiﬁed by mass
spectrometry in Beclin 1 or Mcl-1 complexes immunoprecipitated from 293T cells. (b) Biochemical validation of the interaction between USP9X
and either Beclin 1 or Mcl-1 in 293T cells expressing the indicated constructs. (c) Physical binding between USP9X and both Beclin 1 and Mcl-1 at
the endogenous protein levels in 293T cells. (d,e) Endogenous Beclin 1, Mcl-1 or Bcl-2 were immunoprecipitated from 293T cells transfected with
constructs encoding USP9X WT or the enzymatically inactive USP9X C/S. The ubiquitination status of the immunoprecipitated proteins (d) as well
as protein levels in total cell lysates (e) was assessed in each condition.
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Mcl-1 and Beclin 1 ubiquitination or total protein levels
(Supplementary Fig. 4a,b).
Mcl-1 and Beclin 1 compete for binding USP9X. To get further
insight into the role of USP9X in the regulation of Mcl-1 and
Beclin 1, we next sought to map the binding regions of Mcl-1 and
Beclin 1 on USP9X. To this end, different USP9X fragments
(Fig. 4a) fused to GST and immobilized on glutathione beads
were incubated with lysates of 293T cells expressing either
Flag-tagged Beclin 1 or Flag-tagged Mcl-1. Beclin 1 and Mcl-1
bound the same USP9X fragment as shown in Fig. 4b. The fact
that Mcl-1 is known to interact with both USP9X7 and Beclin
110,11 leaves open the possibility that USP9X could form a
trimeric complex, rather than binding Beclin 1 and Mcl-1
individually. To investigate this possibility, we took advantage of
obatoclax, a known inhibitor of the Bcl-2 family of protein that
has been shown to disrupt the interaction between Mcl-1 and
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Beclin 1 (ref. 27). As shown in Fig. 4c, treatment of 293T cells
with obatoclax, as expected, led to the disruption of the
endogenous Beclin 1/Mcl-1 interaction. Under this condition,
the binding of each individual protein to endogenous USP9X was
not affected. These data indicate that Beclin 1 and Mcl-1 are able
to bind endogenous USP9X independently of each other (Fig. 4c).
Taken together, our data show that Mcl-1 and Beclin 1
reciprocally modulate the ubiquitination of each other with
USP9X being a common interactor whose deubiquitinase activity
stabilizes both of them, and that Mcl-1 and Beclin 1 indepen-
dently bind the same region on USP9X. If the Beclin 1/Mcl-1
inverse co-regulation is a consequence of USP9X activity, one
expectation would be that the relative level of Mcl-1 and Beclin 1
can inﬂuence the binding of each other to USP9X. To test this
hypothesis, we examined the binding between USP9X and either
Beclin 1 or Mcl-1 when the level of one of the latter two was
diminished by RNAi. Depletion of Mcl-1, but not Bcl-2 or Bcl-xL
as control, was associated with enhanced binding between Beclin
1 and USP9X (Fig. 4d). Similarly, enhanced binding between Mcl-
1 and USP9X was detected in immunoprecipitates from 293T
cells that have been depleted of Beclin 1, but not Atg 5 or Atg 7
(Fig. 4e). These results suggest a model in which both Mcl-1 and
Beclin 1 compete with each other for binding USP9X. Decrease in
the level of one relieves the competition for binding USP9X,
which then impacts the ubiquitination and ultimately the protein
level of the other. To further examine this model and to verify
whether USP9X is indeed required for the reciprocal regulation of
Beclin 1/Mcl-1 axis, we knocked down either Beclin 1 or Mcl-1 in
control or USP9X-depleted cells. Stabilization of Mcl-1 or Beclin
1 in response to Beclin 1 or Mcl-1 knockdown, respectively, was
greatly diminished in USP9X-depleted cells, conﬁrming that
USP9X mediates the reciprocal regulation between Mcl-1 and
Beclin 1 (Fig. 4f,g). Our results further show that only a small
fraction of USP9X is present in the membrane compartment in
which most of the Mcl-1 and Beclin 1 localize, adding further
signiﬁcance to the competitive binding model (Supplementary
Fig. 5a,b).
Thus, these results suggest that the reciprocal regulation of
ubiquitination and protein stability between Mcl-1 and Beclin 1 is
associated with competitive displacement of USP9X.
Beclin 1/Mcl-1 axis modulates melanoma growth. Given the
opposite roles of the two proteins in tumour cells, we sought to
examine the implications of the identiﬁed reciprocal regulation of
the Beclin 1/Mcl-1 axis in cancer and particularly explore whether
the reported high levels of Mcl-1 and low levels of Beclin 1 in
certain tumours are inter-dependent and could be explained by
the identiﬁed mechanism of co-regulation.
Expression of Beclin 1 is low in melanoma and the decrease in
Beclin 1 levels was shown to correlate with melanoma progres-
sion21. Conversely, Mcl-1 has been associated with melanoma
progression28 and shown to be critical for survival of melanoma
cells undergoing ER stress29 or anoikis30. Mcl-1 has also been
implicated in mediating resistance of melanoma cells to
radiation31 and several chemotherapeutic agents32–34.
Using patient-derived melanoma as a relevant model of cancer,
we ﬁrst compared the levels of Mcl-1 and Beclin-1 proteins in a
set of primary cultures of patient-derived melanoma cells and
primary human melanocytes. Our data show that melanoma cells,
as compared with melanocytes, express markedly lower levels of
Beclin 1, which correlated with higher levels of Mcl-1. USP9X
levels were comparable in both melanocytes and melanoma cells
(Fig. 5a).
Consistent with a post-translational mode of upregulation, the
elevated levels of Mcl-1 protein in melanoma cell lines did not
correlate with higher Mcl-1 mRNA levels in comparison with
melanocytes and did not generally correlate with the magnitude
of Mcl-1 upregulation among different melanoma cell lines
(Fig. 5b). Importantly, in patient-derived melanoma GaLa 1949
cells, forced expression of Beclin 1 led to enhanced Mcl-1
ubiquitination and decrease in Mcl-1 protein levels (Fig. 5c).
Furthermore, proteasomal, but not lysosomal inhibition
abolished the decline in Mcl-1 levels on Beclin 1 overexpression,
indicating that Beclin 1-driven Mcl-1 degradation is mediated by
the proteasome and is independent of autophagy (Supplementary
Fig. 6).
Next, we investigated the relevance of Beclin 1/Mcl-1 axis to the
tumorigenesis of melanoma. Melanoma cells were dependent on
Mcl-1 upregulation for their proliferation as Mcl-1 knockdown in
GaLa 1949 cells inhibited cell proliferation in vitro and impaired
the growth of tumour xenografts in vivo (Fig. 5d,e). As in 293T
and HeLa cells, Mcl-1 knockdown in GaLa cells was associated
with an increase in Beclin 1 levels (Fig. 5f). This increase in Beclin
1 level was crucial for the observed block in proliferation upon
Mcl-1 extinction, as cells depleted of both Mcl-1 and Beclin 1
proliferated almost normally in vitro and in vivo (Fig. 5d,e).
The Beclin 1/Mcl-1 axis correlates with melanoma progression.
To further explore the observed role of the Beclin 1/Mcl-1 axis in
melanoma, we next assessed Beclin 1 and Mcl-1 protein levels in
lysates derived from either tumour-adjacent normal (N) or
malignant (M) tissues of a set of melanoma patients. Immuno-
blotting analysis further conﬁrmed the speciﬁc modulation of
Beclin 1/Mcl-1 axis in human melanoma (Fig. 6a). Mcl-1 levels
were consistently found higher in tumours as compared with
normal tissues from the same patients. Conversely, in the same
samples Beclin 1 protein levels were consistently found lower in
tumour samples, inversely correlated with Mcl-1 levels.
Moreover, immunohistochemical staining of patient-derived
benign nevi, primary melanoma or metastatic melanoma revealed
a highly signiﬁcant negative rank correlation between Mcl-1 and
Beclin 1 levels (Sperman’s rho¼  0.713, N¼ 43; P¼ 0.000001)
(Fig. 6b,c). Mcl-1 tended to increase and Beclin 1 decreased as
lesions progressed to a more malignant phenotype (w2¼ 11.93;
n¼ 2; P¼ 0.003** and w2¼ 8.09; n¼ 2; P¼ 0.018* at Kruskal
Wallis Test, respectively) (Fig. 6b,c). Even within the more
heterogeneous population of primary melanoma, the inverse rank
correlation between Mcl-1 and Beclin 1 levels was statistically
signiﬁcant (Sperman’s rho¼  0.580; N¼ 28; P¼ 0.001). While
most of the primary melanoma samples expressed low Beclin 1
levels and corresponding high levels of Mcl-1, in the majority of
primary melanoma samples that expressed high level of Beclin 1,
Mcl-1 level was low further conﬁrming their inter-dependency
(Fig. 6d). Moreover, Mcl-1 and Beclin 1 levels showed a slight
trend towards a respectively negative and positive correlation
with survival of patients (Spearman’s rho¼  0.259; N¼ 35;
P¼ 0.133 and rho¼ 0.223; N¼ 35; P¼ 0.198, respectively).
Taken together, these data conﬁrm that in melanoma as a
relevant cancer model, the levels of Mcl-1 and Beclin 1 proteins
are inversely co-regulated as observed in other cell models.
Importantly, our results show that the Beclin 1/Mcl-1 axis is
speciﬁcally modulated during melanoma progression with Beclin
1 level decreasing and Mcl-1 increasing in a statistically
signiﬁcant correlation, strongly suggesting that the change in
the level of the two proteins is closely interdependent.
Discussion
Here we unravel a novel regulatory mechanism that not only is
essential for the regulation of Mcl-1 but also reciprocally regulates
the haplo-insufﬁcient tumour suppressor Beclin 1. In several cell
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models, modulation of either Beclin 1 or Mcl-1 level impacted the
protein level of the other in an inverse manner. Beclin 1 plays an
essential role in the process of autophagy. However, the
modulation of Mcl-1 by Beclin 1 seems to be independent of
autophagy as depletion of other autophagy proteins Atg 5 and
Atg 7 did not lead to changes in Mcl-1 levels and in contrast to
proteasomal inhibition, lysosomal inhibition did not modulate
the decline in Mcl-1 level on Beclin 1 overexpression. This effect
is also independent of the physical interaction between Beclin 1
and Mcl-1. We demonstrate that the inverse reciprocal regulation
between Beclin 1 and Mcl-1 is mediated by competitive binding
to the common deubiquitinase USP9X, which consequently
determines their ubiqitination and proteasomal degradation.
Mcl-1 is upregulated in several types of cancer. Melanoma is an
example of tumours in which Mcl-1 plays crucial tumour-
promoting roles by promoting survival on anoikis30 and
endoplasmic reticulum stress29 and mediating resistance to
radiation31 and several anticancer agents such as Fas32,
dacarbazine33 and ABT737 (ref. 34). Moreover, in the light of
our results and the recent reports that implicate Mcl-1 in the
regulation of autophagy, mitochondrial respiration and ATP
production8,10,11, Mcl-1 may contribute to the survival and
progression of melanoma not only by evading apoptosis but also
by affecting tumour cell energetics.
Several pathways are implicated in the regulation of
Mcl-1 expression, translation and degradation. However, the
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Figure 5 | Beclin 1/Mcl-1 axis modulates melanoma growth in vitro and in vivo. (a) Beclin 1 and Mcl-1 levels in patient-derived melanomas compared with
primary melanocytes. (b) Mcl-1 mRNA levels in patient-derived melanomas and primary melanocytes. Error bars indicate s.e.m. (n¼ 3 for all graphs).
(c) Mcl-1 ubiquitination and degradation on transient expression of Beclin 1 in patient-derived 1949 melanoma cells. Endogenous Mcl-1 was pulled down
from GaLa 1949 transiently transfected with Beclin 1 or empty vector and the level of Mcl-1 ubiquitination as well as total protein levels was assessed by
immunoblotting. (d) In vitro growth of GaLa1949 melanoma cells expressing either scrambled shRNA or Beclin 1 shRNA upon ablation of Mcl-1 with
doxycycline-inducible shRNA. Results are representative of at least three independent experiments. Error bars represent s.e.m. (n¼ 3 for all graphs).
(e) In vivo growth of xenograft tumours derived from cells transduced with the indicated shRNA. Error bars indicate s.e.m. (n¼ 8 per group). After
establishment of xenografts, NSG mice were kept on 1mgml 1 Dox supplemented in the drinking water to induce Mcl-1 shRNA. (f) Beclin 1 and Mcl-1
protein levels in xenografts isolated from animals in (c).
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contribution of these pathways to the observed upregulation of
Mcl-1 in different types of tumours is not clear. In T-cell acute
lymphoblastic leukaemia, follicular lymphoma, small cell lung
carcinomas, ductal and colon adenocarcinoma, high Mcl-1 levels
have mainly been attributed to decreased proteasomal degrada-
tion and increased stability of Mcl-1 protein7,35. Using patient-
derived melanoma cells and tissue samples of benign and
malignant melanocytic lesions at different stages, we show that
melanomas express low levels of Beclin 1 and closely
corresponding high levels of Mcl-1. Our data thus establish a
signiﬁcant inverse correlation between Beclin 1 downregulation
and elevated Mcl-1 levels in melanoma. Importantly, forced
expression of Beclin 1 in patient-derived melanoma cells reduced
Mcl-1 levels and knockdown of either Mcl-1 or Beclin 1 showed
that the modulation of the level of one of the two inversely
impacts levels of the other, clearly conﬁrming the
interdependency of the changes in levels of the two proteins in
melanomas models as sketched in Fig. 7a. Our results also show
that changes in Beclin 1/Mcl-1 axis modulate the proliferation of
melanoma cells and correlate with melanoma progression
(Fig. 7b).
Interestingly, while Beclin 1 and Mcl-1 showed a general trend
to decrease and increase, respectively, with the progression of
melanocytic lesion from benign nevi to metastatic melanoma, in
the samples of primary melanoma with relatively higher level of
Beclin 1, the level of Mcl-1 was accordingly lower and vice versa.
The inverse rank correlation between Mcl-1 and Beclin 1 levels
within this heterogeneous population was statistically signiﬁcant
further conﬁrming the interdependency of the levels of both
proteins. The tight inverse correlation and marked changes in
Mcl-1 and Beclin 1 protein levels in correspondence to each other
suggest that this mechanism of co-regulation is a major
determinant of the Beclin 1/Mcl-1 axis.
The mechanisms by which Beclin 1 suppresses tumorigenesis
remain largely unravelled but generally assumed to be linked to
its essential role in the regulation of autophagy. However, it is not
clear whether autophagy solely accounts for Beclin 1 tumour
suppressive capacity. First, autophagy plays controversial or
possibly dual role in cancer. Second, Beclin 1 is unique among
other autophagy-regulating genes in several ways: unlike most
other autophagy-regulating genes such as Atg3, Atg4C, Atg5,
Atg7, Atg9, Atg16L1 and ULK, BECN1 knockout in mice is
embryonically lethal. Furthermore, in contrast to BECN1
hemizygous animals, Atg5 and Atg7 hemizygous mice do not
develop spontaneous tumours36. It is thus likely that Beclin 1
plays autophagy-independent roles in other processes that may
contribute to its tumour-restraining potential. Indeed,
multifunctional role of Beclin 1 in cellular processes is now
emerging22,23. The ability of Beclin 1 to modulate Mcl-1 level
according to the mechanism we unravel in this study could thus
be an autophagy-independent function of Beclin 1 that
contributes to its tumour suppression capacity.
From another angle, mutations that lead to increased Mcl-1
levels may contribute to tumorigenesis by destabilizing Beclin 1
and thus evading its tumour suppression actions.
With the ability of USP9X to stabilize both the tumour-
promoter Mcl-1 as well as the tumour suppressor Beclin 1, the net
contribution of USP9X to tumorigenesis is probably more
complex than initially thought. Indeed, recent reports suggest
both tumour promoting as well as tumour suppressive functions
for USP9X in different contexts7,37. It will be relevant in
the future to identify the factors that dictate the positive or
negative contribution of USP9X to tumorigenesis, and govern
its substrate speciﬁcity and recruitment, and to study how its
cellular distribution may regulate its availability for interacting
proteins.
Methods
Reagents. The following antibodies were used at working dilution of 1:1,000,
unless otherwise mentioned: anti-LC3 (MPL Biomedicals); anti-p62, anti-Beclin-1
and anti-Mcl-1 (Santa Cruz Biotechnology); anti-Bcl-2 and anti-Bcl-xL (BD
Biosciences); anti-Noxa (Calbiochem); anti-Beclin-1, anti-Atg5, (Novus) and
anti-Atg7 (Epitomics); anti-FLAG (M2-SIGMA, dilution 1:2,000); anti-Vinculin
(h-VIN1, SIGMA, dilution 1:1,0000); anti-Bad (Cell Signaling Technology);
anti-Mule and anti-USP9X (Bethyl Laboratories). Doxycycline, Cycloheximide,
E64d, pepstatin A, Baﬁlomycin A1 and Epoxomicin were purchased from Sigma
Aldrich. Sorafenib, Roscovitine, ABT737 and MG132 were purchased from Selleck
Chemicals. Flag-tagged Mcl-1 was obtained from addgene.org, Flag-tagged Beclin 1
was kindly provided by Dr Beth Levine and USP9X constructs were kindly
provided by Dr Simona Polo.
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Tissue culture. HEK293T cells were acquired from the American Type Culture
Collection (ATCC, Manassas, VA) and were grown in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% fetal bovine serum and 2mM L-glutamine. HeLa
cells and patient-derived melanoma cells were grown in RPMI supplemented with
10% fetal bovine serum and 2mM L-glutamine. Primary human melanocytes Mel
4L, Mel 5L and Mel 56 were isolated from surgical dissection according to the
standardized protocols. Biological samples for research purposes were collected
from patients whose informed consent was obtained in writing according to the
policies of the Ethics Committee of the European Institute of Oncology and reg-
ulations of Italian Ministry of Health. Cells were cultured in McCoy’s 5A Medium
(Invitrogen) supplemented with: 2% FBS, 5 mgml 1 recombinant human Insulin,
5 mgml 1 human Transferrin, 0.5 mgml 1 Hydrocortisone, 20 pm Cholera Toxin
from Vibrio cholerae, 16 nm Phorbol 12-myristate 13-acetate, 10 nm human
Endothelin 1, 10 ngml 1 recombinant human SCF and 1 ngml 1 recombinant
human FGF-2. All cultures were maintained in a humidiﬁed tissue culture incu-
bator at 37 C in 5% CO2.
Establishment of primary cultures from metastatic melanomas. Tumour
specimens (at least 1 g) were put in Petri dishes containing RPMI 1640þ 10% FCS.
After eliminating non-tumour and necrotic parts, tissue was dissected into small
pieces with a scalpel, squeezing each piece for allowing cells to go into suspension.
Cell suspension was ﬁltered through sterile gauze to eliminate macroscopic debris.
Cell suspension was checked for cellular composition: in the presence of signiﬁcant
red blood cell contamination, treatment with ACK (10min on ice) was performed,
the samples were centrifuged and dead cells eliminated by digestion with DNase
and trypsin treatment. Viability of cell suspension was checked by trypan blue
exclusion. In the case when the number of tumour cells obtained from the
mechanical processing was not adequate, the remaining tumour tissue fragments
were treated with a series of enzymes: DNase (200UIml 1), collagenase (0.1%),
hyaluronidase (2.5 UIml 1) and Trypsin (0.5mgml 1). Following 45-minute
incubation at room temperature on a magnetic shaker, cell suspension was ﬁltered
through sterile gauze to remove debris. Cell suspension was recovered from the
supernatant by centrifugation and extensively washed in RPMI 1640þ 10% FCS.
Cells were grown in DMEMþ 10% FBS and were periodically characterized by
immunohystochemistry staining with S100, MelanA and HMB45 antibodies at
various passages during the time they are kept in culture.
RNA interference. siRNA oligos were purchased from Dharmacon. shRNA
pLKO.1 lentiviral constructs were purchased from Open Biosystems. Doxycycline-
inducible shMcl-1 construct was obtained by cloning shMcl-1 sequence # 1
in pLKO-Tet-On lentiviral vector (Open Biosystems). Target sequences are
mentioned in Supplementary Table 1.
Transfection of mammalian cells. 293T cells were transiently transfected using
Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s protocol.
In brief, Lipofectamine 2000 was added to OptiMEM (Invitrogen). Lipofectamine
2000-OptiMEM mix was added dropwise to the plasmid/siRNAs and was allowed
to settle for 15min before it was added to cells.
GaLa 1949 cells were electroporated using Amaxa Nucleofection procedures.
In brief, cells were trypsinized, pelleted and resuspended in nuclefection buffer.
Hundred microlitres of the cell suspension was added to plasmid mix, transferred
to a nucleofection cuvette and immediately nucleofected using Amaxa nucleofector.
Five hundred microlitres of fresh medium was added immediately to the cells after
nucleofection and the nucleofection mix was seeded in a 10-cm dish containing
8ml of pre-warmed medium.
Lentiviral transduction. The pLKO.1 vectors and package plasmids were
co-transfected into packaging HEK293T cells, and the viral supernatants were
collected and used to infect target cells in four 2-h cycles of transduction over
two consecutive days.
Immunoblotting. Total cell lysates were prepared by lysing cells or cell pellets in
SDS–PAGE lysis buffer (100mM Tris.HCl pH6.8, 4%SDS, 20% glycerol, 0.1%
bromophenol blue and 5% b-mercaptoethanol added immediately before use)
followed by heating at 94 C for 7min. Lysates were then electrophoresed on
8–15% SDS–PAGE gels. Gels were run at 100 V (stacking gel)/150 V (separation
gel) on Protean III apparatus (BioRad). Gels were transferred onto nitrocellulose
and probed with the appropriate primary antibody for a variable incubation
time depending on the experimental design, followed by the corresponding
secondary antibodies diluted 1:1,000. The proteins were visualized by enhanced
chemiluminescence (ECL), according to the manufacturer’s instructions
(Amersham Pharmacia Biotech). Representative uncropped scans of blots
generated with the most relevant antibodies used along the different ﬁgures are
presented in Supplementary Fig. 7.
Immunoprecipitation. Cells were lysed in IP lysis buffer (150mM NaCl,
50mM HEPES, pH 7.5, 1% triton X100, 1mM EDTA and 10% glycerol) freshly
supplemented with 1mM DTT, protease inhibitor cocktail (Roche), phosphatase
inhibitor cocktail, 1mM N-ethylmaleimide (NEM). Cell lysates were pre-cleared by
incubation for 2 h at 4 C with pre-immune serum. Supernatants were then
incubated for 4 h with the indicated antibodies at working dilution of 1:100 or
control IgG under constant rotation at 4 C. Beads were washed ﬁve times in ice
cold lysis buffer containing 0.1%Triton X100. Beads were ﬁnally collected by
centrifugation at 5,000 g for 2min and brought up in SDS-PAGE lysis buffer for
further analysis. For in vivo GST pull-down assay, lysates of 293T cells expressing
Flag Beclin 1 or Flag-Mcl-1 were incubated with GST or GST-fused proteins and
20 ml of glutathione-Sepharose 4B at 4 C under constant rotation for 2 h and
washed four times with washing buffer (20mm Tris-HCl, pH 7.4, 150mm NaCl,
0.1% SDS, 1mm EDTA).
Mass spectrometry. Proteins were extracted in SDS-PAGE sample buffer and
separated by one-dimensional electrophoresis using a 4–12% polyacrylamide
Nu-PAGE Novex Bis-tris gel (Life Technologies, Paisley, UK). Peptides were
analysed by RP-chromatography on an Agilent 1100 LC system (Agilent
Technologies) coupled to LTQ-FT ultra (Thermo Fisher Scientiﬁc). MS data were
analysed for protein identiﬁcation using Mascot Daemon v.2.3.2 set up with the
following parameters: Database Swiss prot; Taxonomy Homo Sapiens; Enzyme
trypsin; Max missing cleavage 2; Fixed mod carbamidomethyl (C); Variable mod
oxidation (M); Peptide tolerance 10 p.p.m.; MS/MS tolerance, 0.5 Da; Instrument,
ESI-TRAP.
Cellular fractionation. 293T and GaLa1949 cells were fractionated using the
Qproteome Cell Compartment Kit (Qiagen) according to manufacturer’s protocol.
Immunoﬂuorescence. 293T cells plated on cover slips were permeabilized using
0.2% Triton X100 (in 10% glucose, 25mM PIPES pH 6.8, 1mM EGTA and 1mM
MgCl2) for 5min at room temperature to extract most of the soluable cytosolic
proteins and ﬁxed with 4% paraformaldehyde for 10min at room temperature.
Cells were then washed twice with PBS (pH 7.2) and blocked for 30min with 2%
BSA and then for 1 h at room temperature with ﬂuorochrome-conjugated anti-
bodies diluted 1:100 in blocking buffer, washed three times with PBS. Finally, cells
were stained with DAPI for 5min, mounted with glycerol and examined with Leica
TCS SP2 AOBS confocal microscope with a  60 objective under oil immersion.
Xenografts. NOD scid gamma (NSG) mice (n¼ 8 per group) received single
subcutaneous ﬂank injections of 1 106 patient-derived melanoma cells trans-
duced with different shRNAs and diluted in 200ml saline. Seven days later, mice
were given drinking water containing 1mgml 1 doxycycline and 1% sucrose for
induction of Mcl-1 shRNA expression in vivo. Tumour growth was monitored by
bidimensional measurements using a calliper. Experiments have been done in
accordance with the Italian Laws (D.L.vo 116/92 and following additions), which
enforces EU 86/609 Directive (Council Directive 86/609/EEC of 24 November 1986
on the approximation of laws, regulations and administrative provisions of the
Member States regarding the protection of animals used for experimental and other
scientiﬁc purposes). Mice have been housed accordingly to the guidelines set out in
Commision Recommendation 2007/526/EC 18 June, 2007 on guidelines for the
accommodation and care of animals used for experimental and other scientiﬁc
purposes (project number 02/12).
Immunohistochemistry. Immunohistochemical staining was performed on
3-mm-thick sections of the most representative tumour parafﬁn block, using the
streptavidin-biotin method. Sections were dewaxed, pretreated in a bath (Lab
Vision PT Module) (Bio-Optica, Milan, Italy), with WCAP citrate buffer, pH 6.0
(Bio-Optica), for 40min at 98.5 C, and incubated with 3% H2O2 in TBS to inhibit
endogenous peroxidase. The primary antibodies were then applied at working
dilution of 1:50. To improve the immuno-reactivity of antigens, we used the
UltraVision LP Large Volume Detection System HRP or AP Polymer (Ready-
To-Use) (Bio-Optica), with either diaminobenzidine (Dako, Milan, Italy) for 8min
or new fuchsin for 7min (Bio-Optica), as chromogens, respectively. All sections
were then counterstained with Meyer’s haematoxylin. For each antibody, negative
controls were obtained by replacing the primary antibody with a non-immune
serum at the same concentration. Immunostaining was semi-quantitatively eval-
uated based on both the percentage of positive tumour cells (0, r10%; 1, 410%
andr50%; 2,450%) and the intensity of stain (0, absent; 1, weak; 2, moderate; 3,
strong). Score ranged from 0 to 5 (4 and 5 were considered high scores).
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